137 related articles for article (PubMed ID: 24450579)
21. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
Gianelli U; Iurlo A; Cattaneo D; Bossi A; Cortinovis I; Augello C; Moro A; Savi F; Castelli R; Brambilla C; Bianchi P; Primignani M; Cortelezzi A; Bosari S
Leuk Res; 2015 May; 39(5):525-9. PubMed ID: 25840747
[TBL] [Abstract][Full Text] [Related]
22. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
23. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Ruella M; Salmoiraghi S; Risso A; Carobbio A; Buttiglieri S; Spatola T; Sivera P; Ricca I; Barbui T; Tarella C; Rambaldi A
Exp Hematol; 2013 Jul; 41(7):627-34. PubMed ID: 23542632
[TBL] [Abstract][Full Text] [Related]
24. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States.
Wu N; Yu YF; Chuang CC; Wang R; Benjamin NN; Coultas DB
J Med Econ; 2015 Apr; 18(4):249-57. PubMed ID: 25428658
[TBL] [Abstract][Full Text] [Related]
25. Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population.
Furst DE; Fernandes AW; Iorga SR; Greth W; Bancroft T
J Rheumatol; 2012 Dec; 39(12):2303-9. PubMed ID: 23027885
[TBL] [Abstract][Full Text] [Related]
26. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
27. Health services utilization and cost of retinitis pigmentosa.
Frick KD; Roebuck MC; Feldstein JI; McCarty CA; Grover LL
Arch Ophthalmol; 2012 May; 130(5):629-34. PubMed ID: 22652848
[TBL] [Abstract][Full Text] [Related]
28. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
[TBL] [Abstract][Full Text] [Related]
29. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
Geyer HL; Kosiorek H; Dueck AC; Scherber R; Slot S; Zweegman S; Te Boekhorst PA; Senyak Z; Schouten HC; Sackmann F; Fuentes AK; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Döhner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Paoli C; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Cannon K; Birgegard G; Xiao Z; Xu Z; Zhang Y; Sun X; Xu J; Kiladjian JJ; Zhang P; Gale RP; Mesa RA
Haematologica; 2017 Jan; 102(1):85-93. PubMed ID: 27540137
[TBL] [Abstract][Full Text] [Related]
30. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
31. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis.
Amand C; Tong S; Kieffer A; Kyaw MH
BMC Health Serv Res; 2018 Apr; 18(1):294. PubMed ID: 29678177
[TBL] [Abstract][Full Text] [Related]
32. Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.
Yermakov S; Davis M; Calnan M; Fay M; Cox-Buckley B; Sarda S; Duh MS; Iyer R
J Med Econ; 2015; 18(9):711-20. PubMed ID: 25903661
[TBL] [Abstract][Full Text] [Related]
33. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
[TBL] [Abstract][Full Text] [Related]
34. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective.
Joish VN; Spilsbury-Cantalupo M; Operschall E; Luong B; Boklage S
Appl Health Econ Health Policy; 2013 Jun; 11(3):299-304. PubMed ID: 23580074
[TBL] [Abstract][Full Text] [Related]
35. Clinical Characteristics, Health Care Utilization and Costs Among Men with Primary or Secondary Hypogonadism in a US Commercially Insured Population.
Grabner M; Bodhani A; Khandelwal N; Palli S; Bonine N; Khera M
J Sex Med; 2017 Jan; 14(1):88-97. PubMed ID: 27939338
[TBL] [Abstract][Full Text] [Related]
36. Cerebrovascular events as presenting manifestations of Myeloproliferative Neoplasm.
Ong E; Barraco F; Nighoghossian N; Praire A; Desestret V; Derex L; Vighetto A; Biotti D
Rev Neurol (Paris); 2016 Nov; 172(11):703-708. PubMed ID: 28241944
[TBL] [Abstract][Full Text] [Related]
37. Burden of illness in idiopathic pulmonary fibrosis.
Collard HR; Ward AJ; Lanes S; Cortney Hayflinger D; Rosenberg DM; Hunsche E
J Med Econ; 2012; 15(5):829-35. PubMed ID: 22455577
[TBL] [Abstract][Full Text] [Related]
38. Relationship of diabetes complications severity to healthcare utilization and costs among Medicare Advantage beneficiaries.
Hazel-Fernandez L; Li Y; Nero D; Moretz C; Slabaugh L; Meah Y; Baltz J; Patel NC; Bouchard JR
Am J Manag Care; 2015 Jan; 21(1):e62-70. PubMed ID: 25880269
[TBL] [Abstract][Full Text] [Related]
39. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA
Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927
[TBL] [Abstract][Full Text] [Related]
40. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.
Leal AD; Thompson CA; Wang AH; Vierkant RA; Habermann TM; Ross JA; Mesa RA; Virnig BA; Cerhan JR
Int J Cancer; 2014 Apr; 134(7):1741-50. PubMed ID: 24114627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
